SK Capital Partners, a private investment firm with a focus on the specialty materials, chemicals and healthcare sectors, has completed a controlling strategic investment in Halo Pharmaceutical, a provider of outsourced development and manufacturing services to the global pharmaceutical industry.
 
Halo is a technology-focused contract manufacturing business with applications and capabilities in solid, semi-solid and liquid dosage forms, with a particular focus on controlled substances, and has facilities in the U.S. and Canada.
 
Aaron Davenport, a managing director of SK Capital, said, “We are delighted to partner with the current owners, management and employees of Halo Pharmaceutical to support their growth with additional resources and capital. Halo has grown dramatically since its founding in 2008 and we look forward to supporting its continued growth through investments in people, processes, and infrastructure as well as add-on acquisition opportunities to expand their scale and scope. We see the Halo investment as one which will serve as a long-term platform for growth in this attractive sector.”
 
Mohd Asif, co-founder of Halo, said, “As continuing owners of a significant share in the business, we are excited to partner with an industry-focused investor who can provide capital and resources to further improve our business and support our growth plans as we build our business. By having SK Capital as our partner, Halo will have the resources to acquire strategic assets that will increase our dosage forms offerings, formulation technologies, and enable superior customer service as a one-stop source for formulation development through commercialization.”
 
Halo is the sixth platform company in SK Capital Partners Fund III. Morgan, Lewis & Bockius LLP acted as legal counsel to SK Capital and McCarter & English represented Halo.